SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

The agreement builds on the two sides’ existing collaboration to develop and commercialize the GBP410, a PCV candidate, and ...

SK bioscience and Sanofi, a global healthcare company, extended their partnership to co-develop next-generation pneumococcal ...